Meeting
2017 ASCO Annual Meeting
Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer.
Authors
Georg A. Bjarnason
Sunnybrook Research Institute, Toronto, ON, Canada
Georg A. Bjarnason , Jennifer J. Knox , Christian K. Kollmannsberger , Denis Soulieres , D. Scott Ernst , Pawel Zalewski , Christina M. Canil , Eric Winquist , Sebastien J. Hotte , Scott A. North , Daniel Yick Chin Heng , Robyn Jane Macfarlane , Peter M. Venner , Anil Kapoor , Aaron Richard Hansen , Bernhard J. Eigl , Piotr Czaykowski , Ben Boyd , Lisa Wang , Naveen S. Basappa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT01499121
Citation
J Clin Oncol 35, 2017 (suppl; abstr 4514)
DOI
10.1200/JCO.2017.35.15_suppl.4514
Abstract #
4514
Poster Bd #
192
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Phase II study of individualized sunitinib as first-line therapy for metastatic renal cell cancer (mRCC).
First Author: Georg A. Bjarnason
Poster
2013 ASCO Annual Meeting
A phase II multicenter study of the efficacy and safety of sunitinib given on an individualized schedule as first-line therapy for metastatic renal cell cancer.
First Author: Georg A. Bjarnason
Poster
2018 Gastrointestinal Cancers Symposium
Activity and safety of Nab-FOLFIRI and Nab-FOLFOX as first-line treatment for metastatic pancreatic cancer (phase II NabucCO study).
First Author: Elisa Giommoni
Poster
2012 ASCO Annual Meeting
EVERSUN: A phase II trial of everolimus alternating with sunitinib as first-line therapy for advanced renal cell carcinoma (RCC) (ANZUP trial 0901).
First Author: Ian D. Davis